- Home
- GMRE vs RAPT Comparison
GMRE vs RAPT Comparison
Compare GMRE & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMRE
- RAPT
- Stock Information
- Founded
- GMRE 2011
- RAPT 2015
- Country
- GMRE United States
- RAPT United States
- Employees
- GMRE 26
- RAPT N/A
- Industry
- GMRE Real Estate Investment Trusts
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- GMRE Real Estate
- RAPT Health Care
- Exchange
- GMRE Nasdaq
- RAPT Nasdaq
- Market Cap
- GMRE 438.8M
- RAPT 498.4M
- IPO Year
- GMRE N/A
- RAPT 2019
- Fundamental
- Price
- GMRE $32.20
- RAPT $28.55
- Analyst Decision
- GMRE Buy
- RAPT Strong Buy
- Analyst Count
- GMRE 2
- RAPT 9
- Target Price
- GMRE $40.50
- RAPT $57.00
- AVG Volume (30 Days)
- GMRE 162.9K
- RAPT 584.7K
- Earning Date
- GMRE 11-04-2025
- RAPT 11-06-2025
- Dividend Yield
- GMRE 9.29%
- RAPT N/A
- EPS Growth
- GMRE N/A
- RAPT N/A
- EPS
- GMRE N/A
- RAPT N/A
- Revenue
- GMRE $144,829,000.00
- RAPT N/A
- Revenue This Year
- GMRE $8.69
- RAPT N/A
- Revenue Next Year
- GMRE $5.10
- RAPT N/A
- P/E Ratio
- GMRE N/A
- RAPT N/A
- Revenue Growth
- GMRE 6.04
- RAPT N/A
- 52 Week Low
- GMRE $29.05
- RAPT $5.67
- 52 Week High
- GMRE $45.75
- RAPT $42.39
- Technical
- Relative Strength Index (RSI)
- GMRE 61.53
- RAPT 52.45
- Support Level
- GMRE $31.45
- RAPT $26.78
- Resistance Level
- GMRE $32.94
- RAPT $29.90
- Average True Range (ATR)
- GMRE 0.94
- RAPT 1.64
- MACD
- GMRE -0.28
- RAPT -0.43
- Stochastic Oscillator
- GMRE 79.27
- RAPT 38.42
About GMRE Global Medical REIT Inc.
Global Medical REIT Inc is engaged predominantly in the acquisition of purpose-built healthcare facilities and the leasing of those facilities to physician groups and regional and national healthcare systems. The company's principal business objective is to provide attractive, risk-adjusted returns to its stockholders through a combination of reliable dividends and long-term capital appreciation. Its healthcare facilities are located in secondary markets and suburbs of primary markets and are typically leased to single-tenants under triple-net leases.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.